European Archives - Page 594 of 1189 - European Medical Journal

The biotech boom: fad or forever?

Biotechs have stood as agile hubs for drug discovery, but now they are being coveted by investors.

Standing out in a crowd of digital content

The amount of digital content being created for healthcare professionals has grown exponentially. Medical affairs teams must find a way to cut through the noise with their communications

A cautionary tale of digital transformation

As the pharmaceutical industry embraces digital transformation, new technologies have the potential to sink or swim. How can the industry ensure it’s backing the most effective innovations and not getting stuck in dead ends?

The future of pharmaceutical sales

The COVID-19 pandemic has reshaped pharmaceutical sales, moving from face-to-face to predominantly digital interactions. How can sales reps adapt to multichannel approaches and enhance performance amidst this shift in sales training and team dynamics?

In data we trust: how to nail consent and preference management

The pharmaceutical industry’s digital transformation during the pandemic has fuelled fresh opportunities to collect and harness data, but this venture must be approached with a strong consideration for consent and preference management rules

EMJ Hematology 9 [Supplement 6] 2021

Presentations on sickle cell disease (SCD) at the European Hematology Association (EHA) Virtual Congress 2021.

Sickle Cell Disease: More Than Just Anaemia

Rachel Kesse-Adu highlighted that the hallmark of sickle cell disease (SCD) is painful vaso-occlusive crises (VOCs). These not only cause…

Amgen's Tamika Jean-Baptiste on creating an equitable experience

An interview with Tamika-Jean Baptiste, Vice President and Chief Diversity Officer, Amgen.

Resilience After Rejection

Rejection is always painful, but it is particularly agonising to have a drug rejected at the point of regulatory approval. After spending months researching, preparing, manufacturing and quality checking a drug, only to be sent back to the drawing board, how can companies get back into their creationary swing straight away?

UTIs: Prevalent Yet Overlooked?

Scientists led a focus group study of 29 females experiencing recurrent UTIs in order to gain insight into the gaps in their care…